This review assessed the effects of hormone therapy on bone mineral density in postmenopausal women. The authors concluded that all estrogen preparations appeared to have similar effects on maintaining bone mineral density. Since the treatments were not directly compared, the conclusions are not definitive.
Participants included in the review
Studies in postmenopausal and/or ovariectomised women were eligible for inclusion, regardless of prior fracture history. The classification of women as postmenopausal in the primary studies was accepted. Most of the women in the included studies were aged 50 to 60 years (range: 40 to 76). Most studies were conducted in early-menopausal women with both ovaries, while some included women with hysterectomy and/or bilateral oophorectomy. Some studies did not report whether women who had a surgical menopause were included. The majority of the studies were of Caucasian women.
Outcomes assessed in the review
Studies that reported changes in BMD of the lumbar spine and/or the hip were eligible for inclusion. The outcome of interest was the mean change in BMD from baseline. The most common method of measuring BMD in the included studies was dual-energy X-ray absorptiometry; other methods included dual-photon absorptiometry and single-energy quantitative computed tomography. Studies that measured BMD using roentgenograms, metacarpal measurements, or ultrasound were excluded. The time of the outcome measurement ranged from 2 to 10 years.
How were decisions on the relevance of primary studies made?
Two reviewers selected the studies. It was unclear if this was done independently.
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Assessment of study quality
The authors did not state that they assessed validity.
Data extraction
Two reviewers extracted the data and the data extraction was double-checked. Data on the characteristics of the population and treatments, sample size and drop-outs were extracted. The outcome data were extracted as reported in the primary studies, or were estimated from graphs. Where possible, the data were extracted on an intention-to-treat basis. For each study with sufficient data, the mean percentage change in BMD at the femoral neck, hip and lumbar spine on treatment relative to the control group was extracted.
Methods of synthesis
How were the studies combined?
The studies were grouped a priori according to the pHT intervention and were combined within those groups using a meta-analysis. Meta-analyses were performed without individual study weighting, weighting by sample size and weighting by the ratio of sample size to drop-outs. The pooled mean change in lumbar and femoral BMD, together with the 95% confidence interval (CI), was calculated using a random-effects model. The minimum and maximum change in BMD was also calculated for each pHT group.
How were differences between studies investigated?
Separate meta-analyses were conducted for the following predetermined pHT groups: conjugated equine estrogens; estradiol, estradiol valerate, esterified estrogens, estrone sulphate and estriol; transdermal estradiol; ethinyl estradiol and tibolone. Differences between these groups were tested using an analysis of variance (ANOVA). The relationship between the mean age of the participants and the change in BMD was tested using Spearman's rank order correlation.
Results of the review
Thirty-nine RCTs were included (see Results of the Review for the number of women used in the analysis of each drug class).
The results focused on treatment effects at 2 years.
There were no apparent differences in changes in lumbar spine BMD between the various predetermined treatment groups. Almost all treatment regimens at least maintained or increased lumbar spine and hip BMD at 2 years. The results were similar for analyses adjusting for sample size and drop-outs.
Tibolone appeared to be as effective as any other estrogen regimen (ANOVA P=0.944).
Change in BMD at lumbar spine at 2 years. Analyses weighted by the ratio of sample size to drop-outs.
Conjugated equine estrogens (11 RCTs, more than 1,927 women): the mean change in BMD was 0.076 (95% CI: 0.062, 0.091).
Estradiol, estradiol valerate, esterified estrogens, estrone sulphate and estriol (11 RCTs, more than 2,004 women): the mean change in BMD was 0.072 (95% CI: 0.055, 0.089).
Transdermal estrogens (7 RCTs, 1,047 women): the mean change in BMD was 0.075 (95% CI: 0.063, 0.088).
Tibolone (5 RCTs, 1,150 women): the mean change in BMD was 0.064 (95% CI: 0.030, 0.099).
Ethinyl estradiol (1 RCT, 1,265 women): the mean change in BMD was 0.078 (95% CI: 0.047, 0.110).
There were insufficient data to compare the effects of these classes of pHT on femoral neck or hip BMD, or to compare the effects of adding progestins to a specific estrogen.
